Alnylam pharmaceuticals reports q4 net product revenues of $55.9 mln

Alnylam pharmaceuticals reports fourth quarter and full year 2019 financial results and highlights recent period activity.alnylam pharmaceuticals inc - net product revenues were $55.9 million in q4 2019 representing 21% growth from q3 2019.alnylam pharmaceuticals inc qtrly gaap net loss per common share - basic and diluted $2.47.alnylam pharmaceuticals inc qtrly adjusted loss per share $1.98.alnylam pharmaceuticals inc sees 2020 onpattro net product revenues of $285 million - $315 million.alnylam pharmaceuticals inc sees 2020 net revenues from collaborators of $100 million - $150 million.alnylam pharmaceuticals inc sees 2020 non-gaap research and development and sg&a expenses of $1,025 million - $1,125 million.alnylam pharmaceuticals inc sees 2020 gaap research and development and sg&a expenses of $1,180 million - $1,300 million.
ALNY Ratings Summary
ALNY Quant Ranking